Amiodarone treatment in atrial fibrillation and the risk of incident cancers: A nationwide observational study
| Autor: | Morten Lock Hansen, Frederik Dalgaard, Jannik Langtved Pallisgaard, Gunnar Gislason, Jonathan P. Piccini, Maria D'Souza, Peter Vestergaard Rasmussen, Christian Torp-Pedersen, M. H. Ruwald |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Epidemiology Denmark Amiodarone 030204 cardiovascular system & hematology Risk Assessment 03 medical and health sciences 0302 clinical medicine Risk Factors Interquartile range Neoplasms Physiology (medical) Internal medicine Atrial Fibrillation medicine Humans 030212 general & internal medicine Cancer Aged Retrospective Studies Aged 80 and over Proportional hazards model Cumulative dose business.industry Incidence Hazard ratio Middle Aged medicine.disease Atrial fibrillation Confidence interval Population Surveillance Cohort Female Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents Arrhythmia medicine.drug |
| Zdroj: | Rasmussen, P V, Dalgaard, F, Gislason, G H, Torp-Pedersen, C, Piccini, J, D'Souza, M, Ruwald, M H, Pallisgaard, J L & Hansen, M L 2020, ' Amiodarone treatment in atrial fibrillation and the risk of incident cancers : a nationwide observational study ', Heart Rhythm, vol. 17, no. 4, pp. 560-566 . https://doi.org/10.1016/j.hrthm.2019.11.025 |
| ISSN: | 1547-5271 |
| Popis: | Background: In observational studies, case reports, and animal studies, amiodarone has been associated with incident cancer. Objective: The purpose of this study was to examine whether a dose–response relationship between amiodarone use and the risk of cancer could be ascertained in a large nationwide study cohort. Methods: Using nationwide registers, we included all Danish patients with atrial fibrillation (AF) treated with amiodarone from 1996 to 2014. Exposure was defined both by categories and as a continuous variable of the cumulative defined daily doses (cDDDs) of amiodarone. The associations between amiodarone cDDD and incident cancer, as well as organ-specific types of cancer (skin, liver, lung), were estimated using multivariable Cox regression models and reported as hazard ratios (HR) with 95% confidence intervals (CI) and using cubic restricted spline plots. Results: We included 18,503 patients with a median follow-up time of 8.1 years (interquartile range [IQR] 4.3–12.4). Median age was 70 years (IQR 63–77). A total of 2974 individuals developed cancer during follow-up. We found no association between increasing amiodarone exposure (cDDD 181–400 and cDDD >400) and the hazard of incident cancer (HR 0.95; 95% CI 0.87–1.04; and HR 1.01; 95% CI 0.92–1.10) with reference to patients with cDDD |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|